Tenofovir exalidex - ContraVir Pharmaceuticals

Drug Profile

Tenofovir exalidex - ContraVir Pharmaceuticals

Alternative Names: CMX-157; HDP-Tenofovir; Hexadecyloxypropyl-tenofovir; lipid conjugate TFV(tenofovir); Lipid conjugate YTFV; TXL

Latest Information Update: 22 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chimerix
  • Developer Chimerix; ContraVir Pharmaceuticals
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis B
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B

Highest Development Phases

  • Phase II Hepatitis B
  • Suspended HIV infections

Most Recent Events

  • 06 Aug 2018 Tenofovir exalidex - ContraVir Pharmaceuticals is available for licensing in USA, Europe as of 06 Aug 2018. www.contravir.com
  • 21 Jun 2018 ContraVir Pharmaceuticals plans a dose-range finding study with the optimised second-generation formulation for Hepatitis B treatment (PO)
  • 21 Jun 2018 ContraVir Pharmaceuticals plans a phase III registration programme for Hepatitis B treatment (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top